Mastocytosis is a unique hematologic neoplasm with complex biology and pathology and a variable clinical course. The disease can essentially be divided into cutaneous mastocytosis (CM) and systemic mastocytosis (SM). In adults, SM is diagnosed in most cases and manifests as either indolent or advanced disease. Patients with advanced SM have an unfavorable prognosis with reduced survival. However, so far, little is known about the prevalence of various categories of SM and about prognostic factors. In an attempt to learn more about the behavior and evolution of various forms of CM and SM, the European Competence Network on Mastocytosis (ECNM) initiated a mastocytosis registry in 2012. In this article, the set up and start phase of this registry are described. Until 2018, more than 3000 patients from 12 countries and 25 centers have been enrolled. In a majority of all patients, robust follow-up data and relevant clinical end points are available. Using this data set, a series of registry projects have been launched, with the aim to validate previously identified diagnostic and prognostic variables and to identify new disease-related and patient-related parameters in various forms of mastocytosis. Moreover, the core data set of the registry will be useful to establish multiparametric scoring systems through which prognostication and individualized management of patients with mastocytosis should improve in the foreseeable future.

Allergy Unit Verona University Hospital Verona Italy

Department of Allergology Medical University of Gdansk Gdańsk Poland

Department of Allergology University Medical Center Groningen University of Groningen Groningen The Netherlands

Department of Dermatology and Allergy Biederstein Technische Universität München Munich Germany

Department of Dermatology and Venereology Medical University of Graz Graz Austria

Department of Dermatology University Hospitals Leuven Leuven Belgium

Department of Dermatology University of Cologne Cologne Germany

Department of Dermatology University of Cologne Cologne Germany; Department of Dermatology University of Luebeck Luebeck Germany

Department of Dermatology Venereology and Allergology Medical University of Gdańsk Gdańsk Poland

Department of Hematology Oncology and Stem Cell Transplantation Medical Center Faculty of Medicine University of Freiburg Freiburg Germany

Department of Hematology Oncology and Stem Cell Transplantation Medical Center Faculty of Medicine University of Freiburg Freiburg Germany; German Cancer Consortium partner site Freiburg Freiburg Germany

Department of Hematology Semmelweis University Budapest Hungary

Department of Hematology University Medical Center Groningen University of Groningen Groningen The Netherlands

Department of Hematology Uppsala University Hospital and Department of Immunology Genetics and Pathology Uppsala University Uppsala Sweden

Department of Internal Medicine 1 Division of Hematology and Hemostaseology Medical University of Vienna Vienna Austria; Ludwig Boltzmann Institute for Hematology and Oncology Medical University of Vienna Vienna Austria

Department of Internal Medicine 1 Division of Hematology and Hemostaseology Medical University of Vienna Vienna Austria; Ludwig Boltzmann Institute for Hematology and Oncology Medical University of Vienna Vienna Austria; Department of Companion Animals and Horses Clinic for Internal Medicine and Infectious Diseases University of Veterinary Medicine Vienna Vienna Austria

Department of Internal Medicine 3 Hematology and Oncology Kepler University Hospital Johannes Kepler University Linz Austria

Department of Molecular Medicine and Department of Hematology Oncology University of Pavia and Fondazione IRCCS Policlinico San Matteo Pavia Italy

Department of Oncology Haematology Haemostaseology and Stem Cell Transplantation University Hospital RWTH Aachen Aachen Germany

Division of Allergy and Clinical Immunology University of Salerno Salerno Italy

Division of Hematology Department of Medical Sciences Uppsala University Uppsala Sweden

Division of Hematology Department of Medicine Stanford University School of Medicine Stanford Cancer Institute Stanford Calif

Division of Hematology Istanbul Medical School University of Istanbul Istanbul Turkey

Faculty of Medicine and Health Sciences Department of Immunology Allergology Rheumatology University of Antwerp and Antwerp University Hospital Antwerp Belgium

Hämatologie und Onkologie 3 Medizinische Klinik Universitätsmedizin Mannheim Universität Heidelberg Mannheim Germany

Imagine Institute INSERM U1123 Université Paris Descartes Sorbonne Paris Cité Departement of Hematology Centre national de référence des mastocytoses Hôpital Necker Assistance publique des hôpitaux de Paris Paris France

Laboratory of Hematology Pitié Salpêtrière Hospital Paris France

Necker Pasteur Center for Infectious Diseases and Tropical Medicine and Necker Enfants malades Institut Imagine Centre National de Référence des Mastocytoses Paris Descartes University Paris France

Pediatric Dermatology Unit Department of Medicine University of Padova Padova Italy

Section of Hematology Department of Medicine Verona University Hospital Verona Italy

University Hospital Brno Brno Czech Republic

University Hospital of Leipzig Leipzig Germany

Komentář v

J Allergy Clin Immunol Pract. 2019 Jan;7(1):88. doi: 10.1016/j.jaip.2018.11.001. PubMed

Zobrazit více v PubMed

Escribano L, Akin C, Castells M, Orfao A, Metcalfe DD. Mastocytosis: current concepts in diagnosis and treatment. Ann Hematol. 2002;81:677–90. PubMed

Valent P, Akin C, Sperr WR, Arock M, Lechner K, Bennett JM, et al. Diagnosis and treatment of systemic mastocytosis: state of the art. Br J Haematol. 2003;122:695–717. PubMed

Akin C, Metcalfe DD. Systemic mastocytosis. Annu Rev Med. 2004;55:419–32. PubMed

Valent P, Sperr WR, Schwartz LB, Horny HP. Diagnosis and classification of mast cell proliferative disorders: delineation from immunologic diseases and non-mast cell hematopoietic neoplasms. J Allergy Clin Immunol. 2004;114:3–11. PubMed

Horny HP, Sotlar K, Valent P. Mastocytosis: state of the art. Pathobiology. 2007;74:121–32. PubMed

Metcalfe DD. Mast cells and mastocytosis. Blood. 2008;112:946–56. PubMed PMC

Arock M, Valent P. Pathogenesis, classification and treatment of mastocytosis: state of the art in 2010 and future perspectives. Expert Rev Hematol. 2010;3:497–516. PubMed

Sperr WR, Valent P. Diagnosis, progression patterns and prognostication in mastocytosis. Expert Rev Hematol. 2012;5:261–74. PubMed

Monnier J, Georgin-Lavialle S, Canioni D, Lhermitte L, Soussan M, Arock M, et al. Mast cell sarcoma: new cases and literature review. Oncotarget. 2016;7:66299–309. PubMed PMC

Valent P, Akin C, Metcalfe DD. Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts. Blood. 2017;129:1420–7. PubMed PMC

Valent P, Akin C, Hartmann K, Nilsson G, Reiter A, Hermine O, et al. Advances in the classification and treatment of mastocytosis: current status and outlook toward the future. Cancer Res. 2017;77:1261–70. PubMed PMC

Hartmann K, Escribano L, Grattan C, Brockow K, Carter MC, Alvarez-Twose I, et al. Cutaneous manifestations in patients with mastocytosis: consensus report of the European Competence Network on Mastocytosis; the American Academy of Allergy, Asthma & Immunology; and the European Academy of Allergology and Clinical Immunology. J Allergy Clin Immunol. 2016;137:35–45. PubMed

Valent P, Horny HP, Escribano L, Longley BJ, Li CY, Schwartz LB, et al. Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res. 2001;25:603–25. PubMed

Valent P, Horny H-P, Li CY, Longley JB, Metcalfe DD, Parwaresch RM, et al. Mastocytosis. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. World Health Organization (WHO) classification of tumours of haematopoietic and lymphoid tissues. Lyon, France: IARC Press; 2001. pp. 291–302.

Horny HP, Akin C, Metcalfe DD, Bain BJ, Akin C, Escribano L, et al. Mastocytosis (mast cell disease) In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al., editors. World Health Organization (WHO) classification of tumours. Pathology & genetics. Tumours of haematopoietic and lymphoid tissues. Lyon, France: IARC Press; 2008. pp. 54–63.

Horny HP, Akin C, Arber DA, Peterson LA, Tefferi A, Metcalfe DD, et al. Mastocytosis. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon, France: IARC Press; 2017. pp. 62–9.

Valent P, Akin C, Sperr WR, Escribano L, Arock M, Horny HP, et al. Aggressive systemic mastocytosis and related mast cell disorders: current treatment options and proposed response criteria. Leuk Res. 2003;27:635–41. PubMed

Lim KH, Tefferi A, Lasho TL, Finke C, Patnaik M, Butterfield JH, et al. Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors. Blood. 2009;113:5727–36. PubMed

Pardanani A, Lim KH, Lasho TL, Finke CM, McClure RF, Li CY, et al. WHO subvariants of indolent mastocytosis: clinical details and prognostic evaluation in 159 consecutive adults. Blood. 2010;115:150–1. PubMed

Valent P, Arock M, Bischoff SC, Bühring HJ, Brockow K, Escribano L, et al. The European Competence Network on Mastocytosis (ECNM) Wien Klin Wochenschr. 2004;116:647–51. PubMed

Valent P, Arock M, Bonadonna P, Brockow K, Broesby-Olsen S, Escribano L, et al. European Competence Network on Mastocytosis (ECNM): 10-year jubilee, update, and future perspectives. Wien Klin Wochenschr. 2012;124:807–14. PubMed

Horny HP, Sillaber C, Menke D, Kaiserling E, Wehrmann M, Stehberger B, et al. Diagnostic value of immunostaining for tryptase in patients with mastocytosis. Am J Surg Pathol. 1998;22:1132–40. PubMed

Escribano L, Orfao A, Díaz-Agustin B, Villarrubia J, Cerveró C, López A, et al. Indolent systemic mast cell disease in adults: immunophenotypic characterization of bone marrow mast cells and its diagnostic implications. Blood. 1998;91:2731–6. PubMed

Sperr WR, Escribano L, Jordan JH, Schernthaner GH, Kundi M, Horny HP, et al. Morphologic properties of neoplastic mast cells: delineation of stages of maturation and implication for cytological grading of mastocytosis. Leuk Res. 2001;25:529–36. PubMed

Fritsche-Polanz R, Jordan JH, Feix A, Sperr WR, Sunder-Plassmann G, Valent P, et al. Mutation analysis of C-KIT in patients with myelodysplastic syndromes without mastocytosis and cases of systemic mastocytosis. Br J Haematol. 2001;113:357–64. PubMed

Escribano L, Díaz-Agustín B, Bellas C, Navalón R, Nuñez R, Sperr WR, et al. Utility of flow cytometric analysis of mast cells in the diagnosis and classification of adult mastocytosis. Leuk Res. 2001;25:563–70. PubMed

Valent P, Escribano L, Parwaresch RM, Schemmel V, Schwartz LB, Sotlar K, et al. Recent advances in mastocytosis research: summary of the Vienna Mastocytosis Meeting 1998. Int Arch Allergy Immunol. 1999;120:1–7. PubMed

Böhm A, Födinger M, Wimazal F, Haas OA, Mayerhofer M, Sperr WR, et al. Eosinophilia in systemic mastocytosis: clinical and molecular correlates and prognostic significance. J Allergy Clin Immunol. 2007;120:192–9. PubMed

Pardanani A, Lim KH, Lasho TL, Finke C, McClure RF, Li CY, et al. Prognostically relevant breakdown of 123 patients with systemic mastocytosis associated with other myeloid malignancies. Blood. 2009;114:3769–72. PubMed

Escribano L, Alvarez-Twose I, Sánchez-Muñoz L, Garcia-Montero A, Núñez R, Almeida J, et al. Prognosis in adult indolent systemic mastocytosis: a long-term study of the Spanish Network on Mastocytosis in a series of 145 patients. J Allergy Clin Immunol. 2009;124:514–21. PubMed

Nedoszytko B, Niedoszytko M, Lange M, van Doormaal J, Gleń J, Zablotna M, et al. Interleukin-13 promoter gene polymorphism -1112C/T is associated with the systemic form of mastocytosis. Allergy. 2009;64:287–94. PubMed

Pardanani A, Tefferi A. Systemic mastocytosis in adults: a review on prognosis and treatment based on 342 Mayo Clinic patients and current literature. Curr Opin Hematol. 2010;17:125–32. PubMed

Schwaab J, Schnittger S, Sotlar K, Walz C, Fabarius A, Pfirrmann M, et al. Comprehensive mutational profiling in advanced systemic mastocytosis. Blood. 2013;122:2460–6. PubMed

Damaj G, Joris M, Chandesris O, Hanssens K, Soucie E, Canioni D, et al. ASXL1 but not TET2 mutations adversely impact overall survival of patients suffering systemic mastocytosis with associated clonal hematologic non-mast-cell diseases. PLoS One. 2014;9:e85362. PubMed PMC

Sánchez-Muñoz L, Teodosio C, Morgado JM, Perbellini O, Mayado A, Alvarez-Twose I, et al. Flow cytometry in mastocytosis: utility as a diagnostic and prognostic tool. Immunol Allergy Clin North Am. 2014;34:297–313. PubMed

Hanssens K, Brenet F, Agopian J, Georgin-Lavialle S, Damaj G, Cabaret L, et al. SRSF2-p95 hotspot mutation is highly associated with advanced forms of mastocytosis and mutations in epigenetic regulator genes. Haematologica. 2014;99:830–5. PubMed PMC

Hoermann G, Gleixner KV, Dinu GE, Kundi M, Greiner G, Wimazal F, et al. The KIT D816V allele burden predicts survival in patients with mastocytosis and correlates with the WHO type of the disease. Allergy. 2014;69:810–3. PubMed PMC

Jawhar M, Schwaab J, Schnittger S, Meggendorfer M, Pfirrmann M, Sotlar K, et al. Additional mutations in SRSF2, ASXL1 and/or RUNX1 identify a high-risk group of patients with KIT D816V(+) advanced systemic mastocytosis. Leukemia. 2016;30:136–43. PubMed

Jawhar M, Schwaab J, Hausmann D, Clemens J, Naumann N, Henzler T, et al. Splenomegaly, elevated alkaline phosphatase and mutations in the SRSF2/ASXL1/RUNX1 gene panel are strong adverse prognostic markers in patients with systemic mastocytosis. Leukemia. 2016;30:2342–50. PubMed

Pardanani A, Reichard KK, Zblewski D, Abdelrahman RA, Wassie EA, Morice Ii WG, et al. CD123 immunostaining patterns in systemic mastocytosis: differential expression in disease subgroups and potential prognostic value. Leukemia. 2016;30:914–8. PubMed

Pardanani A, Lasho T, Elala Y, Wassie E, Finke C, Reichard KK, et al. Next-generation sequencing in systemic mastocytosis: derivation of a mutation-augmented clinical prognostic model for survival. Am J Hematol. 2016;91:888–93. PubMed

Naumann N, Jawhar M, Schwaab J, Kluger S, Lübke J, Metzgeroth G, et al. Incidence and prognostic impact of cytogenetic aberrations in patients with systemic mastocytosis. Genes Chromosomes Cancer. 2018;57:252–9. PubMed

Valent P, Sotlar K, Sperr WR, Escribano L, Yavuz S, Reiter A, et al. Refined diagnostic criteria and classification of mast cell leukemia (MCL) and myelomastocytic leukemia (MML): a consensus proposal. Ann Oncol. 2014;25:1691–700. PubMed PMC

Valent P, Akin C, Escribano L, Födinger M, Hartmann K, Brockow K, et al. Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Invest. 2007;37:435–53. PubMed

Akin C, Valent P, Metcalfe DD. Mast cell activation syndrome: proposed diagnostic criteria. J Allergy Clin Immunol. 2010;126:1099–1104.e4. PubMed PMC

Valent P, Akin C, Arock M, Brockow K, Butterfield JH, Carter MC, et al. Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal. Int Arch Allergy Immunol. 2012;157:215–25. PubMed PMC

Valent P. Mast cell activation syndromes: definition and classification. Allergy. 2013;68:417–24. PubMed

Akin C. Mast cell activation syndromes presenting as anaphylaxis. Immunol Allergy Clin North Am. 2015;35:277–85. PubMed

Prognostic impact of expression of CD2, CD25, and/or CD30 in/on mast cells in systemic mastocytosis: a registry study of the European Competence Network on Mastocytosis

Serum chemistry profiling and prognostication in systemic mastocytosis: a registry-based study of the ECNM and GREM

Mast cell leukemia: clinical and molecular features and survival outcomes of patients in the ECNM Registry

Cytogenetic and molecular aberrations and worse outcome for male patients in systemic mastocytosis

Clinical features and survival of patients with indolent systemic mastocytosis defined by the updated WHO classification

Prognostic impact of eosinophils in mastocytosis: analysis of 2350 patients collected in the ECNM Registry

International prognostic scoring system for mastocytosis (IPSM): a retrospective cohort study